cipamfylline has been researched along with Dermatitis, Atopic in 3 studies
*Dermatitis, Atopic: A chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. It is manifested by lichenification, excoriation, and crusting, mainly on the flexural surfaces of the elbow and knee. In infants it is known as infantile eczema. [MeSH]
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Andersson, C; Engell, K; Felding, J; Hegardt, P; Ladefoged, LG; Larsen, J; Nielsen, SF; Poulsen, TD; Refer, P; Søhoel, A; Sørensen, MD; Thormann, T; Vinggaard, AM | 1 |
Alenius, H; Kemp, K; Kvist, PH; Lauerma, A; Lehto, M; Savinko, T; Wolff, H | 1 |
Gilbert, M; Griffiths, CE; Traulsen, J; Van Leent, EJ | 1 |
1 review(s) available for cipamfylline and Dermatitis, Atopic
Article | Year |
---|---|
Discovery and early clinical development of 2-{6-[2-(3,5-dichloro-4-pyridyl)acetyl]-2,3-dimethoxyphenoxy}-N-propylacetamide (LEO 29102), a soft-drug inhibitor of phosphodiesterase 4 for topical treatment of atopic dermatitis.
Topics: Acetamides; Crystallography, X-Ray; Cyclic Nucleotide Phosphodiesterases, Type 4; Dermatitis, Atopic; Dose-Response Relationship, Drug; Drug Discovery; Humans; Models, Molecular; Molecular Structure; Phosphodiesterase 4 Inhibitors; Pyridines; Structure-Activity Relationship | 2014 |
1 trial(s) available for cipamfylline and Dermatitis, Atopic
Article | Year |
---|---|
Randomized comparison of the type 4 phosphodiesterase inhibitor cipamfylline cream, cream vehicle and hydrocortisone 17-butyrate cream for the treatment of atopic dermatitis.
Topics: Administration, Topical; Adult; Anti-Inflammatory Agents; Dermatitis, Atopic; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydrocortisone; Male; Middle Aged; Ointments; Phosphodiesterase Inhibitors; Prospective Studies; Recurrence; Statistics, Nonparametric; Xanthines | 2002 |
1 other study(ies) available for cipamfylline and Dermatitis, Atopic
Article | Year |
---|---|
A murine model of epicutaneous protein sensitization is useful to study efficacies of topical drugs in atopic dermatitis.
Topics: Administration, Topical; Animals; Anti-Allergic Agents; Anti-Inflammatory Agents; Betamethasone Valerate; Calcineurin Inhibitors; Cytokines; Dermatitis, Atopic; Disease Models, Animal; Enterotoxins; Female; Immunoglobulin A; Immunoglobulin E; Immunohistochemistry; Immunosuppressive Agents; Mice; Mice, Inbred BALB C; Ovalbumin; Phosphodiesterase Inhibitors; Proteins; Reverse Transcriptase Polymerase Chain Reaction; Skin; Tacrolimus; Xanthines | 2010 |